Recall of Cobas b 123 POC system

According to U.S. Food and Drug Administration, this recall involved a device in United States that was produced by Roche Diagnostics Operations, Inc..

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    75709
  • Event Risk Class
    Class 2
  • Event Number
    Z-1077-2017
  • Event Initiated Date
    2015-09-03
  • Event Date Posted
    2017-01-23
  • Event Status
    Terminated
  • Event Country
  • Event Terminated Date
    2017-06-05
  • Event Source
    USFDA
  • Event Source URL
  • Notes / Alerts
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Extra notes in the data
    Electrode measurement, blood-gases (pco2, po2) and blood ph - Product Code CHL
  • Reason
    Under specific settings, an issue may occur during simultaneous sensor cartridge and fluid pack change on the cobas b 123 <2> poc system and cobas b 123 <4> poc system. the issue occurs when the software function [autoqc as follow-up] is configured to run all three levels of autoqc only after a fluid pack change, but not after a sensor cartridge change. when both are changed simultaneously, starting with the sensor cartridge and followed by the fluid pack, the analyzer carries out only the follow-up actions associated with the sensor cartridge change after completing the change workflow. as a result, no follow-up autoqc is performed and the three expected autoqc measurements for the fluid pack change are not carried out. without running quality control, there is a remote possibility that system issues would not be detected and wrong results would not be excluded on all parameters: ph, po2, pco2, na+, k+, ca++, cl-, glu, lac, hct, so2, o2hb, cohb, methb, hhb, and bili.
  • Action
    Roche issued an Analyzer Bulletin on September 3, 2015, to all affected Consignees. The recall notifications included a description of the reason for the recall, affected product, and consignee responsibilities; the notification did not include instructions for responding to the notification. Actions Required " Follow the workaround outlined in this Analyzer Bulletin to avoid the described issue. " File this Analyzer Bulletin for future reference. Questions Please contact the Roche Support Network Customer Support Center at 1-800-526-2272 if you have questions about the information contained in this Analyzer Bulletin.

Device

  • Model / Serial
    Models: cobas b 123 <2> POC system: 05122252001 cobas b 123 < 4 > POC system: 05122287001 Serial numbers: 11074  2274  2550  2302  2304  2309  1253  2420  2337  2147  2389  2418  2425  1749  2462  2338  2339  1850  2328  2500  1374  2301  1349  2400  2344  2350  1860  1941  2006  2128
  • Product Classification
  • Device Class
    2
  • Implanted device?
    No
  • Distribution
    Nationwide Distribution including CA, LA, NE, PR, SC, TX, VA, and WV
  • Product Description
    Cobas b 123 POC system || The cobas b 123 POC system is a fully automated POC system for whole blood in vitro measurement of pH, blood gases (B3G), electrolytes Nat, K+, iCaWt (ISE), hematocrit (THct), metabolites (Glu, Lac), total hemoglobin (tHb), hemoglobin derivatives (O2Hb, HHb, COT~b, MetHb), and oxygen saturation (SO2). In addition, the cobas b 123 POC system calculates derived parameters. It is dedicated for use in a Point-of-Care environment and laboratory. The integrated AutoQC module and the oximeter module are available as an option
  • Manufacturer

Manufacturer

  • Manufacturer Address
    Roche Diagnostics Operations, Inc., 9115 Hague Rd, Indianapolis IN 46256-1025
  • Manufacturer Parent Company (2017)
  • Source
    USFDA